drugset / Trial / NCT04360174

CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension

NCT04360174

Phase 1 Completed 19 enrolled Ocular Therapeutix, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

To assess the safety, tolerability and efficacy of a single sustained release dose of OTX-TIC, a sustained release travoprost drug product, in subjects with primary open-angle glaucoma or ocular hypertension.

Timeline

Start
2018-04-25
Primary completion
2021-05-24
Completion
2021-05-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Travoprost Other / unclassified 5 ug Other
Subject Travoprost Other / unclassified 15 ug Other
Subject Travoprost Other / unclassified 26 ug Other